Aldeyra Therapeutics
ALDX
45 hedge funds and large institutions have $77.1M invested in Aldeyra Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 4 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
18% more funds holding
Funds holding: 38 → 45 (+7)
16% more capital invested
Capital invested by funds: $66.5M → $77.1M (+$10.6M)
2.65% more ownership
Funds ownership: 51.14% → 53.79% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.21M |
| 2 |
6CM
683 Capital Management
New York
|
+$645K |
| 3 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$486K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$433K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$266K |
| 2 |
Renaissance Technologies
New York
|
-$239K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$95K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$19.7K |
| 5 |
AIS
AlphaOne Investment Services
West Chester,
Pennsylvania
|
-$16K |
ALDX Hedge Fund Activity: Q1 2018 in Review
45 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2018, worth a combined $77.1M — up 16% from $66.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALDX positions and 4 closed out — a net gain of 7 holders — while 19 added to existing stakes and 5 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $1.21M. The largest seller was Sphera Funds Management, cutting an estimated $266K.
- 45 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2018, up from 38 in Q4 2017.
- Funds reported $77.1M of Aldeyra Therapeutics stock for Q1 2018, up 16% quarter-over-quarter.
- 11 funds opened new Aldeyra Therapeutics positions in Q1 2018 and 4 closed out, a net change of +7 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2018 was Mangrove Partners, an estimated $1.21M added.
- The largest Aldeyra Therapeutics seller in Q1 2018 was Sphera Funds Management, an estimated $266K sold.
Based on aggregated 13F filings for Q1 2018.